Auvelity Patent Expiration

Auvelity is a drug owned by Axsome Therapeutics Inc. It is protected by 120 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 20, 2043. Details of Auvelity's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844797 Combination of dextromethorphan and bupropion for treating depression
Apr, 2043

(18 years from now)

Active
US11839612 Compounds and combinations thereof for treating neurological and psychiatric conditions
Mar, 2043

(18 years from now)

Active
US12042473 Compounds and combinations thereof for treating neurological and psychiatric conditions
Feb, 2043

(18 years from now)

Active
US11752144 Compounds and combinations thereof for treating neurological and psychiatric conditions
Feb, 2043

(18 years from now)

Active
US12036191 Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
Feb, 2043

(18 years from now)

Active
US11986444 Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
Feb, 2043

(18 years from now)

Active
US11730706 Treatment of depression in certain patient populations
Jan, 2043

(18 years from now)

Active
US11883373 Treatment of depression in certain patient populations
Jan, 2043

(18 years from now)

Active
US11717518 Bupropion dosage forms with reduced food and alcohol dosing effects
Jan, 2043

(18 years from now)

Active
US11925636 Bupropion dosage forms with reduced food and alcohol dosing effects
Jan, 2043

(18 years from now)

Active
US11896563 Bupropion and dextromethorphan for reduction of suicide risk in depression patients
Dec, 2041

(17 years from now)

Active
US10940124 Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Active
US10925842 Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Active
US10780064 Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Active
US10966942 Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Active
US10780066 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9474731 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9375429 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(9 years from now)

Active
US9421176 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9408815 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9763932 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11311534 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9205083 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(9 years from now)

Active
US9707191 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10898453 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11433067 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9700528 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9457023 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9238032 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(9 years from now)

Active
US11096937 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11298352 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10966941 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11298351 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11090300 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10894047 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10064857 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11291665 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11291638 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10786469 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11253492 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10881657 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10874663 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10799497 Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(9 years from now)

Active
US11058648 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11273133 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10864209 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10806710 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10881624 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10786496 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11020389 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11185515 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10945973 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11285146 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11285118 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10596167 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(9 years from now)

Active
US11439636 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9314462 Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9198905 Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11426401 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11426370 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11419867 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10772850 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11273134 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11253491 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11234946 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10548857 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11229640 Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(9 years from now)

Active
US10874665 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10933034 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10251879 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10092561 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(9 years from now)

Active
US10894046 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11191739 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10874664 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10080727 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11197839 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11147808 Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(9 years from now)

Active
US11207281 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11141416 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11141388 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11213521 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11129826 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11123343 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10966974 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US10512643 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10463634 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10105361 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10105327 Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US10092560 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9968568 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11969421 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11478468 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11541048 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11524007 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11534414 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11779579 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11617728 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11596627 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11497721 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US12109178 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11524008 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9370513 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11617747 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11541021 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11517542 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11517543 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11510918 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11382874 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11364233 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9457025 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(9 years from now)

Active
US10058518 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9278095 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9867819 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9168234 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9861595 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US9700553 Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(9 years from now)

Active
US11357744 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US11344544 Bupropion as a modulator of drug activity
Nov, 2034

(9 years from now)

Active
US9486450 Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(9 years from now)

Active
US8569328 Compositions and methods comprising tilidine or related compounds and dextromethorphan
Oct, 2033

(8 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Auvelity's patents.

Given below is the list of recent legal activities going on the following patents of Auvelity.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 Jul, 2024 US10894047
Payment of Maintenance Fee, 4th Year, Large Entity 02 Jul, 2024 US10881657
Change in Power of Attorney (May Include Associate POA) 02 Jul, 2024 US11426401
Email Notification 02 Jul, 2024 US11426401
Email Notification 02 Jul, 2024 US11439636
Change in Power of Attorney (May Include Associate POA) 02 Jul, 2024 US11439636
Payment of Maintenance Fee, 4th Year, Large Entity 01 Jul, 2024 US10881624
Change in Power of Attorney (May Include Associate POA) 27 Jun, 2024 US10780066
Change in Power of Attorney (May Include Associate POA) 27 Jun, 2024 US10786469
Email Notification 27 Jun, 2024 US10780066


FDA has granted several exclusivities to Auvelity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Auvelity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Auvelity.

Exclusivity Information

Auvelity holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Auvelity's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Auvelity's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Auvelity's generic, the next section provides detailed information on ongoing and past EP oppositions related to Auvelity patents.

Auvelity's Oppositions Filed in EPO

Auvelity has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 31, 2021, by Elkington And Fife Llp. This opposition was filed on patent number EP15861189A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15861189A May, 2021 Elkington and Fife LLP Granted and Under Opposition


US patents provide insights into the exclusivity only within the United States, but Auvelity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Auvelity's family patents as well as insights into ongoing legal events on those patents.

Auvelity's Family Patents

Auvelity has patent protection in a total of 30 countries. It has a significant patent presence in the US with 60.8% of its patents being US patents. Click below to unlock the full patent family tree for Auvelity.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Auvelity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 20, 2043 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Auvelity Generics:

There are no approved generic versions for Auvelity as of now.

How can I launch a generic of Auvelity before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Auvelity's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Auvelity's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Auvelity -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
45 mg/105 mg 22 Dec, 2022 1 07 Jan, 2040





About Auvelity

Auvelity is a drug owned by Axsome Therapeutics Inc. It is used for treating major depressive disorder by administering dextromethorphan and bupropion in combination. Auvelity uses Bupropion Hydrochloride; Dextromethorphan Hydrobromide as an active ingredient. Auvelity was launched by Axsome in 2022.

Can you believe Auvelity received compensation for the extended wait time during the regulatory approval process?

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

Approval Date:

Auvelity was approved by FDA for market use on 18 August, 2022.

Active Ingredient:

Auvelity uses Bupropion Hydrochloride; Dextromethorphan Hydrobromide as the active ingredient. Check out other Drugs and Companies using Bupropion Hydrochloride; Dextromethorphan Hydrobromide ingredient

Treatment:

Auvelity is used for treating major depressive disorder by administering dextromethorphan and bupropion in combination.

Dosage:

Auvelity is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
105MG;45MG TABLET, EXTENDED RELEASE Prescription ORAL